LONDON GlaxoSmithKline will stop paying doctors to promote its medicines amid Chinese government accusations that the U.K. drugmaker bribed physicians, a year after the company admitted to marketing offenses in the U.S.
GSK plans to stop direct payments to doctors for giving speeches and attending medical meetings by early 2016, the London-based company said Tuesday in a statement. The company will also introduce a new compensation program for sales representatives who deal directly with those who prescribe medicines.
“In terms of gathering good will and repairing image, it’s definitely a step in the right direction, and I would expect other large pharma companies to start looking at this policy as well,” said Sudip Hazra, an analyst in Kepler Cheuvreux’s environmental, social and governance research team in Paris. The policy is also “a good long-term measure to protect the company” given the risk of more corruption investigations in other emerging markets, Hazra said.
GSK employs about 4,000 people in Research Triangle Park, where it has its North American headquarters. It also has about 600 workers at its manufacturing plant in Zebulon.
The overhaul in marketing practices comes as GSK seeks to repair its reputation amid a corruption investigation of GSK in China, begun in July. Authorities there allege that the drugmaker bribed hospitals, doctors and officials. Some senior executives appear to have acted outside GSK’s processes and controls to defraud the company and the Chinese health care system, Chief Executive Officer Andrew Witty said July 24.
“It is imperative that we continue to actively challenge our business model at every level to ensure we are responding to the needs of patients and meeting the wider expectations of society,” Witty said in the statement Tuesday.
The Chinese inquiry was largely responsible for GSK’s sales of pharmaceuticals and vaccines in that market plunging 61 percent in the three months through September. GSK’s troubles came after the company paid a record $3 billion last year to resolve U.S. allegations that it improperly promoted medicines and failed to report safety information.
GSK revised its incentive compensation program for U.S. sales representatives, saying that in 2011, it had done away with the link between sales goals and bonuses. Bonuses are now based on selling competency, customer evaluations and overall performance of the representative’s business unit.
Dubbed “Patient First,” the new marketing strategy involves a team-based approach focused on educating and having discussions with doctors and pharmacists about the product, as opposed to individual sales representatives pushing prescriptions. A similar program will now be introduced in all countries in which GSK operates by early 2015, the company said Tuesday.
“The experiment in the U.S. must have delivered benefits in terms of doctor interaction and credibility, and that’s why they’d like to do this globally,” said Mark Clark, an analyst at Deutsche Bank in London. “And with China in the background, it sends out a good message about being patient-centric rather than chasing the prescription at all costs.”
The new incentive compensation system could place GSK at a competitive disadvantage, Kepler’s Hazra said. Sales representatives may be put off by the approach, hindering GSK’s recruiting ability, Clark said.
GSK will continue to pay doctors for conducting company-sponsored clinical research, advisory activities and market research, it said. The company already discloses speaking and consulting fees it pays doctors in countries including the U.S., Australia, the U.K. and Japan.
The Charlotte Observer welcomes your comments on news of the day. The more voices engaged in conversation, the better for us all, but do keep it civil. Please refrain from profanity, obscenity, spam, name-calling or attacking others for their views.
Have a news tip? You can send it to a local news editor; email firstname.lastname@example.org to send us your tip - or - consider joining the Public Insight Network and become a source for The Charlotte Observer.Read moreRead less